Product logins

Find logins to all Clarivate products below.


Postherpetic Neuralgia | Treatment Algorithms | Claims Data Analysis | US | 2017

Postherpetic Neuralgia (PHN) is an inflammatory neuropathic pain condition characterized by pain persisting for more than 30 days after the onset of the herpes zoster rash caused by a byproduct of varicella zoster virus reactivation. Symptoms include dysethesia, spontaneous burning pain; shooting, tic-like pain. PHN treatment guidelines recommend antiepileptic drugs (namely, Lyrica and gabapentin), followed by tricyclic antidepressants (e.g., amitriptyline), and topical lidocaine patches (e.g., the 5% lidocaine patch). Given the substantial percentage of patients with inadequate pain relief, together it is important to understand use of current therapies in newly diagnosed and recently treated PHN patients thought the use of national patient-level claims data.

Questions Answered

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed PHN patients?
  • What are the quarterly trends in prescribing among recently treated and new diagnosed PHN patients?
  • How have Lyrica, gabapentin, the 5% lidocaine patch, and Qutenza been integrated into the treatment algorithm?
  • What proportion of PHN patients receive drug therapy within a year of diagnosis, and how quickly?
  • What percentage of patients progress to later lines of therapy within a year of diagnosis?
  • What percentage of PHN patients are treated with monotherapy versus combination therapy?
  • What are the most widely used combination therapies? · What are the product-level compliance and persistency rates among drug-treated patients with PHN?

Product Description

Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Related Market Assessment Reports

Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…